Skip to main content

Table 3 Comparison of clinical outcomes in those patients who had gut dominated by bifidobacterium versus bacteroides genera using mixed effect models correcting for age, gender, sputum organisms (except for FEV1) and clustering by patient

From: Gut Bifidobacteria enrichment following oral Lactobacillus-supplementation is associated with clinical improvements in children with cystic fibrosis

Clinical outcomes

Dominant genus

Bifidobacterium versus Bacteroides (95% CI)

P

Bifidobacterium

Bacteroides

N

Adjusted estimate ± sd

N

Adjusted estimate ± sd

Pulmonary exacerbations (N)

19

1.6 ± 1.5

13

2.9 ± 1.6

IRR = 0.55 (0.25 to 0.82)

0.01

FEV1 (percentage of predicted value)

22

103.48 ± 1.39

15

83.97 ± 1.48

Coef = 20.00 (8.05 to 31.92)

0.001

Calprotectin (µg/g of feces)

19

80.05 ± 61.43

13

107.73 ± 37.97

Coef =  − 16.53 (− 26.80 to − 6.26)

0.002

Days of prescribed antibiotics in past 6-months (N)

19

25.8 ± 6.8

13

60.3 ± 5.9

IRR = 0.43 (0.22 to 0.69)

0.04

  1. Data includes dominant genus and clinical outcomes reported at baseline and 12-month visits